An observational follow-up study for: a phase III randomized, placebo-controlled clinical trial to assess the safety and efficacy of odanacatib (MK-0822) to reduce the risk of fracture in osteoporotic postmenopausal women treated with vitamin D and calcium (Protocol 018) (MK-0822-083)